Role of Fibrocytes in Chronic Obstructive Pulmonary Disease (FIREBROB)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01196832|
Recruitment Status : Unknown
Verified October 2014 by University Hospital, Bordeaux.
Recruitment status was: Recruiting
First Posted : September 9, 2010
Last Update Posted : October 30, 2014
Chronic obstructive pulmonary disease (COPD) is a frequent airway disease characterized by both bronchial inflammation and remodelling.
Bronchial mucosa is infiltrated by macrophages, neutrophils and lymphocytes. In addition, the number of eosinophils can be also increased during exacerbation.
Airway remodelling is an abnormal tissue repair following bronchial inflammation, which contributes to none reversible pathological features, such as bronchial and peri-bronchial fibrosis. It also influences the prognosis of COPD and its mechanisms remain largely unknown. The role of fibrocytes has been demonstrated in the pathophysiology of asthma, lung fibrosis or pulmonary hypertension. However, the recruitment of blood fibrocytes and their involvement in COPD airway remodelling remain unknown.
|Condition or disease||Intervention/treatment|
|Chronic Obstructive Pulmonary Disease||Procedure: blood sample Procedure: Clinical and functional evaluation|
|Study Type :||Observational|
|Estimated Enrollment :||160 participants|
|Observational Model:||Case Control|
|Official Title:||Role of Fibrocytes in the Bronchial Remodeling of Chronic Obstructive Pulmonary Disease|
|Study Start Date :||March 2011|
|Estimated Primary Completion Date :||September 2016|
|Estimated Study Completion Date :||November 2016|
Chronic obstructive pulmonary disease patients
COPD patients with exacerbation will be recruited during hospitalization in Intensive care unit or as outpatients in the clinical investigation centre of the CHU de Bordeaux.
Inclusion visit: blood sample for fibrocytes analysis. Second visit 2 months ± 7 days after the exacerbation: clinical and functional evaluation (plethysmography, TLCO, arterial gaz), blood sample for fibrocytes analysis.
Procedure: blood sample
blood sample for fibrocytes analysisProcedure: Clinical and functional evaluation
Plethysmography, Carbon monoxide capacity of transfer , arterial gaz
Subjects without any history of lung disease and with normal lung function testing
Procedure: blood sample
blood sample for fibrocytes analysis
- Number of circulating blood fibrocytes [ Time Frame: Day 1 ]Sampling of blood in Chronic obstructive pulmonary disease patients
- Number of circulating blood fibrocytes [ Time Frame: 2 months ]Sampling of blood in Chronic obstructive pulmonary disease patients
- Characterization of fibrocytes [ Time Frame: Day 1 and at 2 months ]Sampling of blood
- Differenciation of blood fibrocytes [ Time Frame: Day 1 and at 2 months ]Sampling of blood
- Chemotactism of blood fibrocytes [ Time Frame: Day 1 and at 2 months ]Sampling of blood
- Number of exacerbation [ Time Frame: 12 months after V2 ]
- Mortality [ Time Frame: 12 months after V2 ]
- Annual decline of ventilatory function [ Time Frame: 12 months after V2 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01196832
|Contact: Patrick BERGER, PUPH||(0)5 57 65 65 13|
|Contact: David LEGROS||(0)5 57 65 65 email@example.com|
|CHU de Bordeaux||Recruiting|
|Pessac, France, 33604|
|Contact: Patrick BERGER, PUPH (0)5 57 65 65 13|
|Contact: David LEGROS firstname.lastname@example.org|
|Principal Investigator: Patrick BERGER, PUPH|
|Principal Investigator:||Patrick BERGER, PUPH||University Hospital Bordeaux (France)|